Who are L-T4+T3 (thyroid tablet)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Armour Thyroid, Levothyroxine-Na + iodide, TT3-LITE Regimen (L-TT3).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l-t4-t3-thyroid-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

L-T4+T3 (thyroid tablet) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

L-T4+T3 (thyroid tablet) (L-T4+T3 (thyroid tablet)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement therapy. Area: Endocrinology.

marketed Thyroid hormone replacement therapy Thyroid hormone receptors (TR-alpha, TR-beta) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

L-T4+T3 (thyroid tablet) (L-T4+T3 (thyroid tablet)) — Zhongshan Hospital Xiamen University. L-T4+T3 combination therapy replaces deficient thyroid hormones by providing both levothyroxine (T4) and liothyronine (T3) to restore normal thyroid hormone levels.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
L-T4+T3 (thyroid tablet) TARGET	L-T4+T3 (thyroid tablet)	Zhongshan Hospital Xiamen University	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha, TR-beta)
Armour Thyroid	Armour Thyroid	AbbVie	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha and TR-beta)
Levothyroxine-Na + iodide	Levothyroxine-Na + iodide	Sanofi	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha and TR-beta)
TT3-LITE Regimen (L-TT3)	TT3-LITE Regimen (L-TT3)	University of Arkansas	phase 3	Thyroid hormone replacement therapy	Thyroid hormone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement therapy class)

AbbVie · 1 drug in this class
Sanofi · 1 drug in this class
University of Arkansas · 1 drug in this class
Zhongshan Hospital Xiamen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-T4+T3 (thyroid tablet) — Competitive Intelligence Brief. https://druglandscape.com/ci/l-t4-t3-thyroid-tablet. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing